AI cervical cancer screener hits 42% sales growth with million-woman milestone
TruScreen Group's AI-powered cervical cancer screening device grew sales 42% in fiscal 2026, the company said in May. The device has now screened over 1 million women globally.
The company targets low- and middle-income countries where cervical cancer screening infrastructure remains limited. TruScreen operates through partnerships and a recurring revenue model, positioning itself in a $7.9 billion market.
Clinical validation supports the device's performance. The company's strategy centers on scaling across regions with high disease burden but limited diagnostic capacity.
What this means for sales teams
The results show how AI-driven medical devices can generate sustained revenue growth in underserved markets. For sales professionals, the model demonstrates the power of recurring revenue streams tied to clinical need rather than one-time equipment sales.
TruScreen's partnership approach offers a template: instead of direct sales forces in each region, the company builds channel relationships that handle local distribution and customer support. This reduces upfront sales costs while extending geographic reach.
The million-woman screening milestone reflects volume at scale-the kind of metric that validates market demand and justifies continued investment in sales infrastructure.
Learn more about AI for Sales or explore an AI Learning Path for Sales Representatives to understand how AI-driven growth strategies work across industries.
Your membership also unlocks:
